Axsome Therapeutics, Inc. AXSM

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes.

Our innovative CNS portfolio is anchored by three U.S. Food and Drug Administration (FDA) approved commercial products: AUVELITY® for the treatment of major depressive disorder (MDD), SUNOSI® for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO® for the acute treatment of migraine with or without aura in adults. Total revenues from our three commercial products totaled $638.5 million for 2025, representing 66% annual growth compared to 2024.

Last close 145.04 2026-10-23
Market cap $7.60B 2026-06-30 share count
52-week range 123.50 - 260.19

Valuation FY2025 figures against the last close

P/S11.9x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-3.68

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $638.5M$385.7M$270.6M$50.0M——————
Cost of revenue ———$5.2M——————
Gross profit ———$44.8M——————
R&D $183.3M$187.1M$97.9M$57.9M$58.1M$70.2M$53.6M$23.5M$20.0M$21.2M
SG&A $570.6M$411.4M$323.1M$159.3M$66.6M$28.9M$13.6M$9.4M$7.2M$6.3M
Total operating expenses $805.3M$666.3M$502.4M$229.8M$124.7M$99.1M$67.2M$32.8M$27.2M$27.5M
Operating income -$166.8M-$280.6M-$231.8M-$179.8M-$124.7M-$99.1M-$67.2M-$32.8M-$27.2M-$27.5M
Interest expense $15.9M$21.6M$20.0M$9.7M——————
Pre-tax income -$183.7M-$287.1M-$238.3M-$187.1M-$130.4M-$102.9M-$68.3M-$31.0M-$28.9M-$27.2M
Income tax $530.0K$85.0K$960.0K$0$0$0$0$0$0$0
Net income -$183.2M-$287.2M-$239.2M-$187.1M-$130.4M-$102.9M-$68.3M-$31.0M-$28.9M-$27.2M
EPS, basic -3.68-5.99-5.27-4.60-3.47-2.77————
EPS, diluted -3.68-5.99-5.27-4.60-3.47-2.77-2.01-1.15-1.27-1.42
Shares, diluted (wtd. avg.) 49.7M47.9M45.4M40.7M37.6M37.2M————

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $322.9M$315.4M$386.2M$200.8M$86.5M$183.9M$220.0M———
Receivables $224.5M$142.0M$94.8M$37.7M——————
Inventory $27.9M$15.7M$15.1M$4.3M——————
Total current assets $589.0M$485.1M$504.3M$245.6M$86.5M$184.0M$220.4M$15.2M$35.3M$38.0M
Property, plant and equipment $562.0K$584.0K$846.0K$722.0K$283.8K$52.6K$30.6K$51.8K$68.1K$100.7K
Goodwill $12.0M$12.0M$12.0M$10.3M——————
Other intangibles $40.5M$46.9M$53.3M$59.7M——————
Total assets $689.8M$568.5M$588.2M$331.5M$87.8M$186.1M$220.5M$15.4M$35.6M$38.2M
Accounts payable $65.5M$72.0M$40.7M$38.6M$13.1M$13.5M$10.9M$3.7M$3.4M$4.1M
Short-term debt $70.0M$0————$2.6M$3.3M$3.3M$269.2K
Total current liabilities $378.8M$230.1M$138.9M$96.6M$23.1M$23.4M$24.5M$10.8M$12.2M$7.2M
Long-term debt $117.7M$180.7M$178.1M$94.3M$49.1M$48.3M$17.3M$3.6M$6.7M$9.5M
Total liabilities $601.5M$511.5M$397.3M$221.9M$72.2M$72.3M$41.8M$14.4M$18.8M$16.6M
Retained earnings -$1.31B-$1.12B-$835.6M-$596.3M-$409.2M-$278.8M-$175.9M-$107.6M-$76.6M-$47.6M
Total equity $88.3M$57.0M$191.0M$109.6M$15.6M$113.8M$178.7M$937.9K$16.7M$21.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$93.4M-$128.4M-$145.1M-$116.5M-$108.2M-$78.5M-$46.4M-$30.1M-$26.5M-$21.3M
Depreciation and amortisation $503.0K$532.0K$459.0K$263.0K$76.0K$23.9K$37.3K$48.9K$42.6K$20.5K
Stock-based compensation $93.8M$85.2M$62.6M$37.7M$20.8M$14.8M$6.1M$1.8M$2.1M$2.0M
Capital expenditure $480.0K$270.0K$582.0K$702.0K$308.0K$45.9K$16.1K$32.7K$9.9K$104.6K
Investing cash flow -$480.0K-$270.0K-$582.0K-$53.7M-$308.0K-$45.9K-$16.1K-$32.7K-$9.9K-$104.6K
Financing cash flow $101.5M$57.8M$331.0M$284.6M$11.1M$42.4M$252.4M$10.0M$23.9M$10.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-177610.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M -250M 0 250M 500M 750M Net income, FY2016: -27.2M Net income, FY2017: -28.9M Net income, FY2018: -31M Net income, FY2019: -68.3M Net income, FY2020: -102.9M Net income, FY2021: -130.4M Revenue, FY2022: 50M Gross profit, FY2022: 44.8M Net income, FY2022: -187.1M Revenue, FY2023: 270.6M Net income, FY2023: -239.2M Revenue, FY2024: 385.7M Net income, FY2024: -287.2M Revenue, FY2025: 638.5M Net income, FY2025: -183.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — $50.0M $270.6M $385.7M $638.5M
Gross profit — — — — — — $44.8M — — —
Net income -$27.2M -$28.9M -$31.0M -$68.3M -$102.9M -$130.4M -$187.1M -$239.2M -$287.2M -$183.2M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%